drugset / Trial / NCT04672434
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
Timeline
- Start
- 2020-11-19
- Primary completion
- 2024-11-22
- Completion
- 2024-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sym021 | Monoclonal antibody | — | — |
| Subject | Sym024 | Unknown | — | — |